Literature DB >> 22427055

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.

Renato D Lopes1, Richard C Becker, L Kristin Newby, Eric D Peterson, Elaine M Hylek, Christopher B Granger, Mark Crowther, Tracy Wang, Antonio C Carvalho, Otavio Berwanger, Roberto R Giraldez, Gilson Soares Feitosa, Jorge Pinto Ribeiro, Eduardo Darze, Renato A K Kalil, Marianna Andrande, Fabio Villas Boas, Jadelson Andrade, Ana Thereza Rocha, Robert A Harrington, Antonio C Lopes, David A Garcia.   

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Fourth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, from October 20-21, 2011. This scientific program was developed by clinicians for clinicians and was promoted by three major clinical research institutes: the Brazilian Clinical Research Institute, the Duke Clinical Research Institute of the Duke University School of Medicine, and Hospital do Coração Research Institute. Comprising 2 days of academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427055     DOI: 10.1007/s11239-012-0700-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  117 in total

1.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Kenneth W Mahaffey; Daniel M Wojdyla; Kevin Carroll; Richard C Becker; Robert F Storey; Dominick J Angiolillo; Claes Held; Christopher P Cannon; Stefan James; Karen S Pieper; Jay Horrow; Robert A Harrington; Lars Wallentin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

2.  PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.

Authors:  Deborah Cook; Maureen Meade; Gordon Guyatt; Stephen D Walter; Diane Heels-Ansdell; William Geerts; Theodore E Warkentin; D Jamie Cooper; Nicole Zytaruk; Shirley Vallance; Otavio Berwanger; Marcelo Rocha; Ismael Qushmaq; Mark Crowther
Journal:  J Crit Care       Date:  2011-04       Impact factor: 3.425

3.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

4.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

5.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

Review 6.  Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Authors:  J M Siller-Matula; B Jilma; K Schrör; G Christ; K Huber
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

7.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

8.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

10.  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Authors:  Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman
Journal:  Circulation       Date:  2008-08-31       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.